Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):e161-3. doi: 10.1016/j.clml.2014.06.004. Epub 2014 Jun 11.
No abstract available

Keywords: Mitogen-activated protein kinase; Mutation; Refractory myeloma; V600E; Vemurafenib.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Boronic Acids / administration & dosage
  • Bortezomib
  • Carcinoma, Squamous Cell
  • Combined Modality Therapy
  • Dexamethasone / administration & dosage
  • Disease Progression
  • Fatal Outcome
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Indoles / therapeutic use*
  • Lenalidomide
  • Male
  • Mediastinal Neoplasms / drug therapy
  • Mediastinal Neoplasms / pathology
  • Mediastinal Neoplasms / therapy
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / etiology
  • Multiple Myeloma / genetics
  • Mutation, Missense*
  • Neoplasm Proteins / genetics*
  • Neoplasms, Second Primary
  • Osteolysis / etiology
  • Osteolysis / pathology
  • Osteolysis / radiotherapy
  • Palliative Care
  • Plasmacytoma / drug therapy
  • Plasmacytoma / pathology
  • Plasmacytoma / therapy
  • Point Mutation*
  • Protein Kinase Inhibitors / therapeutic use*
  • Proto-Oncogene Proteins B-raf / genetics*
  • Pyrazines / administration & dosage
  • Remission Induction
  • Salvage Therapy*
  • Sulfonamides / therapeutic use*
  • Thalidomide / administration & dosage
  • Thalidomide / analogs & derivatives
  • Transplantation, Autologous
  • Treatment Outcome
  • Vemurafenib

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Indoles
  • Neoplasm Proteins
  • Protein Kinase Inhibitors
  • Pyrazines
  • Sulfonamides
  • Vemurafenib
  • Thalidomide
  • Bortezomib
  • Dexamethasone
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • Lenalidomide